Cargando…
Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69
Temozolomide, a DNA methylating drug, is currently being used first-line in glioblastoma therapy. Although the mode of action of this so-called S(N)1 alkylating agent is well described, including the types of induced DNA damage triggering the DNA damage response and survival and death pathways, some...
Autor principal: | Kaina, Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966492/ https://www.ncbi.nlm.nih.gov/pubmed/31717973 http://dx.doi.org/10.3390/biomedicines7040090 |
Ejemplares similares
-
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019) -
Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics
por: Beltzig, Lea, et al.
Publicado: (2022) -
Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells
por: Beltzig, Lea, et al.
Publicado: (2022) -
Comment in Response to “Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy etc. by B. Kaina”
por: Westhoff, Mike-Andrew, et al.
Publicado: (2020) -
Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
por: He, Yang, et al.
Publicado: (2019)